Development of the Perinatal Depression Inventory (PDI)-14 using item response theory: a comparison of the BDI-II, EPDS, PDI, and PHQ-9

Brodey, Benjamin B.; Goodman, Sherryl H.; Baldasaro, Ruth E.; Brooks-DeWeese, Amy; Wilson, Mary H.; Brodey, Inger Sigrun; Doyle, Nora M.

doi:10.1007/s00737-015-0553-9

Cited by 22 publications

(23 citation statements)

References 27 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of the EPDS as the measure for probable depression diagnosis may be less ideal as an assessment of depressive symptoms in the postnatal period may due to extra postpartum duties associated with the arrival of a newborn. Possible limitations of the EPDS tool and an alternative device were recently highlighted [ 52 ], similar to previously published shortcomings [ 53 , 54 ] and alternatives to the EPDS [ 55 , 56 ]. Nevertheless, it is important to note that even if a screening tool is error-free, its interpretation (i.e., the assignment of a positive or negative outcome) may still be incorrect [ 57 ].…”

Section: Discussionsupporting

confidence: 74%

Determinants of antenatal depression and postnatal depression in Australia

et al. 2018

View full text Add to dashboard Cite

BackgroundDepression is a leading source of morbidity and health loss in Australian women. This study investigates the determinants of antenatal depressive symptoms and postnatal depressive symptoms in an Australian population, including people from culturally and linguistically diverse (CALD) backgrounds.MethodThe study used a retrospective cohort of mothers of all live births in public health facilities in 2014 (N = 17,564) within South Western Sydney Local Health District and Sydney Local Health District in New South Wales, Australia. Prevalence of antenatal and postnatal depressive symptoms were estimated for the cohort. Multivariate logistic regression models were conducted to investigate the sociodemographic, psychological and health service determinants of antenatal and postnatal depressive symptoms, measured using the Edinburgh Postnatal Depression Scale (EPDS).ResultsThe prevalence of antenatal and postnatal depressive symptoms was 6.2% and 3.3% of the cohort, respectively. Significant risk factors for maternal depressive symptoms during pregnancy were, a lack of partner support, history of intimate partner violence, being from the CALD population and low socioeconomic status. Self-reported antenatal depressive symptoms were strongly associated with postnatal depressive symptoms. Risk factors for postnatal depressive symptoms were similar to those for antenatal depressive symptoms, as well as assisted delivery.ConclusionFactors relating to demographic and psychosocial disadvantage were associated with subsequent antenatal and postnatal depressive symptoms in New South Wales, Australia. Our study suggests that screening for probable depression and timely referral for expert assessment of at-risk mothers may be an effective strategy to improve maternal mental health outcomes.

show abstract

Section: Discussionsupporting

confidence: 74%

Determinants of antenatal depression and postnatal depression in Australia

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The current study suffers some limitations. While the BDI‐II is widely used and well validated as self‐report assessment of depression (Brodey et al ., ; Hobkirk et al ., ; Wu & Huang, ), and demonstrated high reliability and construct validity in the present sample, it does reflect the individual's own report of depressive symptoms. Despite evidence that self‐report measures are quite accurate in assessing emotions and behaviors (Spain, Eaton & Funder, ), a structured clinical interview with fathers who scored above referral cut‐offs on the BDI‐II would have made possible the confirmation of a diagnosis of depression.…”

Section: Discussionmentioning

confidence: 99%

“…The BDI‐II has also been validated for use with mothers pre‐ and postpartum (e.g. Boyd, Le & Somberg, ; Brodey, Goodman, Baldasaro, et al ., ; Tandon, Cluxton‐Keller, Leis & Perry, ). Although high scores on the BDI‐II do not suffice for diagnosing depression in clinical practice, it was used here as reference measure for suspected depression.…”

Section: Methodsmentioning

confidence: 99%

Symptoms of depression in Swedish fathers in the postnatal period and development of a screening tool

Psouni

Agebjörn

Linder

2017

Scandinavian J Psychology

View full text Add to dashboard Cite

Methods for detecting depression in fathers after the birth of their child are scarce. The Edinburgh Postnatal Depression Scale (EPDS), used to screen mothers for postpartum depression (PPD), lacks somatization and externalizing items. This potentially decreases its sensitivity in detecting depression in fathers, as many men actually express depression with somatization or externalizing symptoms. The present study assessed depressive symptoms in fathers of children 0-18 months old, and evaluated whether addressing both typical depression and externalizing, so-called "depressive equivalent" symptoms, might be more suitable for such assessment. The Beck Depression Inventory-II (BDI-II), EPDS, and Gotland Male Depression Scale (GMDS) were responded to by 447 Swedish fathers online. Among participants, 27% reported depressive symptoms above the BDI-II cut-off suggestive of depression. Most fathers reported both traditional and depressive equivalent symptoms and a subgroup expressed exclusively depressive equivalent symptoms. Consistently, a scale combining items from the EPDS and GMDS showed higher sensitivity than the EPDS alone in identifying fathers with elevated depressive symptoms, at equal levels of specificity. Our findings suggest that a combination of EPDS and depressive equivalent symptom items results in a more suitable instrument for screening for depression in fathers during the postnatal period.

show abstract

“…The Centers for Disease Control and Prevention (CDC) in the United States (U.S.) reported an overall PPD prevalence of 11.5% which ranged from 8 % to 20.1% [13]. The determination of PPD prevalence is complicated by the fact that rates are calculated using different diagnostic criteria, especially when defining time of onset or offset, and a variety of screening tools and tool cut-offs are used [14][15][16][17]. The Edinburgh Postnatal Depression Scale (EPDS) [18] is the most widely used self-report screening tool, a ten-item scale that has been validated for use during pregnancy and postpartum [19] and in multiple languages.…”

Section: Prevalencementioning

confidence: 99%

Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development

et al. 2019

View full text Add to dashboard Cite

Postpartum depression is one of the most common complications of childbirth. Untreated postpartum depression can have substantial adverse effects on the well-being of the mother and child, negatively impacting child cognitive, behavioral, and emotional development with lasting consequences. There are a number of therapeutic interventions for postpartum depression including pharmacotherapy, psychotherapy, neuromodulation and hormonal therapy among others, most of which have been adapted from the treatment of major depressive disorder outside of the peripartum period. Current evidence of antidepressant treatment for postpartum depression is limited by the small number of randomized clinical trials, underpowered samples and lack of longterm follow-up. The peripartum period is characterized by rapid and significant physiological change in plasma levels of endocrine hormones, peptides and neuroactive steroids. Evidence supporting the role of neuroactive steroids and GABA in the pathophysiology of postpartum depression led to the investigation of synthetic neuroactive steroids and their analogs as potential treatment for postpartum depression. Brexanolone, a soluble, proprietary, intravenous preparation of synthetic allopregnanolone has been developed. A recent series of open-label and placebocontrolled randomized clinical trials of brexanolone in postpartum depression demonstrated rapid reduction of depressive symptoms, and have led to the submission for regulatory approval to the US Food and Drug Administration (decision due in March 2019). SAGE-217, an allopregnanolone analog, with oral bioavailability, was recently tested in a randomized, double-blind, placebocontrolled phase 3 study in severe postpartum depression, with reportedly positive results. Finally,

show abstract

Development of the Perinatal Depression Inventory (PDI)-14 using item response theory: a comparison of the BDI-II, EPDS, PDI, and PHQ-9

Cited by 22 publications

References 27 publications

Determinants of antenatal depression and postnatal depression in Australia

Determinants of antenatal depression and postnatal depression in Australia

Symptoms of depression in Swedish fathers in the postnatal period and development of a screening tool

Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development

Contact Info

Product

Resources

About